Agenus Inc. (NASDAQ:AGEN - Free Report) - Stock analysts at B. Riley raised their Q2 2024 earnings per share estimates for Agenus in a report released on Wednesday, May 8th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn ($0.02) per share for the quarter, up from their previous estimate of ($4.92). B. Riley currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for Agenus' current full-year earnings is ($9.70) per share. B. Riley also issued estimates for Agenus' Q3 2024 earnings at ($2.82) EPS, Q4 2024 earnings at $1.39 EPS, FY2024 earnings at ($4.66) EPS, FY2025 earnings at ($6.82) EPS, FY2026 earnings at ($4.13) EPS, FY2027 earnings at ($2.27) EPS and FY2028 earnings at $0.27 EPS.
Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($2.20). The business had revenue of $83.80 million during the quarter, compared to the consensus estimate of $54.21 million.
Other equities analysts have also issued reports about the company. StockNews.com began coverage on Agenus in a research note on Wednesday, April 17th. They set a "hold" rating for the company. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Agenus in a research report on Tuesday, May 7th.
Check Out Our Latest Stock Report on Agenus
Agenus Stock Performance
Shares of AGEN stock traded up $0.60 during midday trading on Monday, reaching $11.09. 395,016 shares of the company were exchanged, compared to its average volume of 700,286. The company's 50 day moving average price is $10.57 and its two-hundred day moving average price is $13.10. The company has a market cap of $232.89 million, a P/E ratio of -0.86 and a beta of 1.25. Agenus has a 12 month low of $4.78 and a 12 month high of $42.60.
Insiders Place Their Bets
In other news, insider Garo H. Armen bought 25,000 shares of the firm's stock in a transaction on Thursday, February 15th. The stock was bought at an average cost of $13.00 per share, for a total transaction of $325,000.00. Following the completion of the acquisition, the insider now directly owns 31,298 shares in the company, valued at approximately $406,874. The purchase was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 4.80% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of AGEN. SG Americas Securities LLC purchased a new position in shares of Agenus during the 3rd quarter valued at $36,000. PCG Wealth Advisors LLC grew its stake in Agenus by 65.7% in the fourth quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 18,850 shares in the last quarter. RPO LLC acquired a new position in Agenus in the 4th quarter worth about $43,000. First Command Advisory Services Inc. purchased a new stake in shares of Agenus during the 3rd quarter worth about $80,000. Finally, Ables Iannone Moore & Associates Inc. acquired a new stake in shares of Agenus during the 4th quarter valued at about $65,000. Hedge funds and other institutional investors own 61.46% of the company's stock.
Agenus Company Profile
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
